

CONTENTS

<i>Foreword</i>	(vii)
<i>Preface</i>	(ix)
<i>Acknowledgement</i>	(xi)
<i>Contributors</i>	(xiii)

CHAPTER 1

Drug Delivery using Polymeric and other Carrier Systems

Y. Singh, M. Chaurasia and Manish K. Chourasia..... 1-42

1.1 Introduction.....	1-2
1.2 Basic Methods of Polymeric Nanoparticle Production.....	2-18
1.2.1 Dispersion of Preformed Polymers to Form PNPs..	3-16
1.2.1.1 Emulsification/Solvent Evaporation	3-5
1.2.1.2 Nanoprecipitation.....	5-8
1.2.1.3 Salting-Out.....	8-10
1.2.1.4 Dialysis	10-12
1.2.1.5 Ionic Gelation Method	12-13
1.2.1.6 Preparation of Nanoparticles with a Membrane Contactor.....	13-14
1.2.1.7 New Techniques based on Supercritical or Compressed Fluids	15-16
1.2.2 Polymerization of Monomers	16-18
1.2.2.1 Emulsion Polymerization.....	17-18
1.3 Nanocrystals.....	18-23
1.3.1 Approaches to Formulating Nanocrystals	20-23
1.3.1.1 Precipitation Method.....	20
1.3.1.2 Homogenization Method.....	20-22
1.3.1.3 Pearl/Ball-Milling Technology for the Production of Drug Nanocrystals.....	22
1.3.1.4 Production of Drug Nanocrystal Compounds by Spray-Drying	23

1.4 Nanocapsules	23-28
1.4.1 Preparation.....	25-28
1.4.1.1 Nanocapsules Formulation by Interfacial Polymerization.....	25-27
1.4.1.2 Nanocapsules Obtained from Preformed Polymers.....	27-28
1.5 Nanofibers.....	28-34
1.5.1 Polymers used for Development of Nanofibers ..	29-30
1.5.2 Electrospinning.....	30-32
1.5.3 Spontaneous Assembly.....	32-33
1.5.4 Temperature Induced Phase Separation	33-34
1.6 Nanorods.....	34-37
1.6.1 Synthesis of Nanorods.....	35-37
1.6.1.1 Seed-Mediated Growth	35
1.6.1.2 Synthesis of Nanorods at High Temperatures in Organic Solvents	36
1.6.1.3 Template Method	36
1.6.1.4 Electrochemical Method	36-37
1.6.1.5 Zinc Oxide (ZnO) Nanorods	37
References	37-42

CHAPTER 2

Dendrimers in Drug Delivery

<i>Umesh Gupta</i>	43-71
2.1 Background and Introduction	43-46
2.2 Dendrimer Synthesis.....	46-49
2.2.1 Divergent Approach	46-47
2.2.2 Convergent Approach.....	47-48
2.2.3 Double Exponential Growth.....	48
2.2.4 'Click' Chemistry Approach	48-49
2.3 Molecular Structure and Properties	49-51

2.4	Characterization	51-52
2.5	Major Classes of Dendrimers.....	52-57
2.5.1	Polyamidoamine (PAMAM) Dendrimers	52-53
2.5.2	Polypropylene(imine) (PPI) Dendrimers.....	53-55
2.5.3	Peptide Dendrimers	55-56
2.5.4	Triazine Dendrimers.....	56
2.5.5	Glyco or Carbohydrate Dendrimers	56
2.5.6	Tecto Dendrimers	56
2.5.7	Chiral Dendrimers	57
2.5.8	Miscellaneous.....	57
2.6	Biomedical Applications.....	57-66
2.6.1	Solubilization of Insoluble Drugs.....	57-58
2.6.2	Drug Delivery Applications	58-63
2.6.2.1	Controlled and Targeted Drug Delivery	59-61
2.6.2.2	Oral Drug Delivery	61
2.6.2.3	Transdermal Drug Delivery	62
2.6.2.4	Ocular and Pulmonary Drug Delivery	63
2.6.3	Applications in Gene Delivery	64
2.6.4	Applications as MRI Contrast Agent	64-65
2.6.5	Applications in Boron Neutron Capture Therapy (BNCT).....	65-66
2.6.6	Applications in Photodynamic Therapy (PDT).....	66
	<i>References</i>	66-71

CHAPTER 3

Liposomes: Manufacturing and Applications

Varsha Tilwani, Priyanka Jain, Darshana Jain,

Nishi Mody and Aviral Jain..... **72-110**

3.1	Introduction.....	72
3.1.1	Structure of Liposomes	73

(xviii) Contents

3.1.2	Composition of Liposomes.....	73-75
3.1.2.1	Phospholipids.....	73-75
3.1.2.2	Cholesterol.....	75
3.1.3	Bilayer Properties of Liposomes.....	76
3.2	Method of Preparation of Liposomes.....	76-90
3.2.1	Mechanical Dispersion.....	76-81
3.2.1.1	Hand Shaking Method.....	76-77
3.2.1.2	Non Shaking Method.....	77-78
3.2.1.3	Freeze Drying Method.....	78
3.2.1.4	Micro-Emulsification Method.....	78
3.2.1.5	Sonicated Vesicles.....	78-79
3.2.1.6	French Pressure Cell.....	79-80
3.2.1.7	High Pressure Membrane Extrusion....	80-81
3.2.2	Solvent Dispersion Methods.....	81-86
3.2.2.1	Ethanol Injection Method.....	82
3.2.2.2	Ether Injection Method.....	82-83
3.2.2.3	Double Emulsion Vesicles.....	83-84
3.2.2.4	Multivesicular Liposomes.....	85
3.2.2.5	Reverse Phase Evaporation Method....	85-86
3.2.2.6	Stable Plurilamellar Vesicles (SPLV).....	86
3.2.3	Detergent Removal (Depletion) Method.....	86-87
3.2.4	Active Loading.....	87-88
3.2.5	pH Gradient Drug Loading.....	89
3.2.6	Lyophilization of Liposomes.....	89-90
3.3	Liposomes Scale up and Manufacturing Issues.....	90-93
3.3.1	Removal of Traces of Organic Solvents.....	90-91
3.3.2	Protection of Phospholipids from Oxidation.....	91
3.3.3	Removal of Endotoxins.....	91-92
3.3.4	Removal of Un-entrapped Drug.....	92
3.3.5	Sterilization of Liposomes.....	93
3.4	Characterizations of Liposomes.....	93-97
3.4.1	Chemical Analysis.....	93-95
3.4.1.1	Quantitative Determination of Phospholipid.....	93-94

3.4.1.2	Estimation of Phospholipid Oxidation ..	94-95
3.4.1.3	Quantitation of α -Tocopherol.....	95
3.4.2	Physical Characterization	95-97
3.4.2.1	Lamellarity Determination.....	95
3.4.2.2	Size Determination.....	95-96
3.4.2.3	Determination of Residual Organic Phase in Phospholipid Mixtures.....	96
3.4.2.4	Surface Charge of Utilized Lipids	96-97
3.4.2.5	Percent Drug Encapsulation.....	97
3.5	Applications of Liposomes	97-103
3.5.1	Liposomes used in Antimicrobial Drug Delivery	97-99
3.5.1.1	Viral	97-98
3.5.1.2	Protozoal	98
3.5.1.3	Bacterial	98-99
3.5.1.4	Fungal	99
3.5.2	Use of Liposomes in Cancer Therapy	99-101
3.5.3	Liposomes in Oxygen Transport	101
3.5.4	Liposomes in Enzyme Replacement Therapy	101
3.5.5	Liposomes in Metal Poisoning	101
3.5.6	Liposomes in Diagnostic Applications.....	102
3.5.7	Liposomes to Inhibit Immune Reactions.....	102
3.5.8	Liposomes as Vaccine Carriers	102-103
3.6	Stability of Liposomes	103-105
3.6.1	Chemical Stability	104-105
3.6.2	Physical Stability.....	105
3.7	Conclusion	105
	References	106-110

CHAPTER 4

Carbon Nanotubes and their Applications in Drug Delivery

J.G. Meher, Nitin K. Jain and Manish K. Chourasia..... 111-143

4.1	Introduction.....	111-113
-----	-------------------	---------

(xx) *Contents*

4.2	Brief History of CNTs	114
4.3	Classification	115-117
4.4	Physicochemical Properties of CNTs	118-120
4.5	Manufacturing Methods.....	121-124
4.5.1	Production Methods	121-123
4.5.1.1	Electric-arc Discharge	121-122
4.5.1.2	Catalytic Chemical Vapor Deposition	122
4.5.1.3	Laser Ablation.....	122-123
4.5.2	Purification Techniques.....	123-124
4.6	Functionalization of CNTs.....	124-128
4.7	Characterization Parameters	128-129
4.7.1	Size, Charge and Size Distribution.....	128
4.7.2	Morphology	128-129
4.7.3	Spectroscopic Evaluation	129
4.7.4	Miscellaneous Characterization	129
4.8	Release of Drug from CNTs	129-131
4.9	Fate of CNTs <i>In vivo</i>	131-133
4.10	Applications	133-138
4.10.1	Role of CNTs in Drug Delivery	134-135
4.10.2	Boosting up Immunity and Vaccination	136
4.10.3	Gene Delivery.....	136-137
4.10.4	Imaging Tools.....	137-138
4.10.5	Biomedical Applications	138
4.11	Toxicity Aspects	138-140
4.12	Future Prospects.....	140
	<i>References</i>	140-143

CHAPTER 5

Target Oriented Nano-Carrier based Drug Delivery Systems

	<i>P. Khare, V.K. Pawar and M. Chaurasia</i>	144-165
5.1	Introduction.....	144-145

5.2 Rationale for Nanocarrier based Targeted Drug Delivery	145-150
5.2.1 Passive Targeting	147
5.2.2 Active Targeting.....	147-150
5.3 Biological Processes Involved in Drug Targeting by Nanocarriers	150-160
5.3.1 Organ and Tissue Targeting	150-151
5.3.2 Cellular Targeting.....	151-152
5.3.3 Intracellular Targeting.....	152-154
5.3.4 Cellular Uptake and Processing.....	154-155
5.3.4.1 Cellular Phagocytosis.....	154
5.3.4.2 Cellular Pinocytosis	155
5.3.4.3 Receptor-mediated Endocytosis.....	155
5.3.5 Transport across Epithelium.....	156-158
5.3.6 Extravasation	158-159
5.3.7 Lymphatic Uptake	159-160
5.4 Pharmacokinetic and Pharmacodynamic Considerations	160-162
5.4.1 Blood Flow Rate.....	161
5.4.2 Distribution.....	161
5.4.3 Clearance/Excretion	161-162
References	162-165

CHAPTER 6

Pegylation and Long-Circulating Nanoparticles

<i>Neha Gupta and Prem N. Gupta</i>	166-185
6.1 Introduction.....	166-168
6.2 Properties of Ideal Pegylating Agent	169
6.3 Types of Conjugates	170
6.4 Designing Pegylated Conjugates	170-172
6.5 Bioactivity of Pegylated Conjugates.....	172-175

6.6	Rational of Long Circulation	175-177
6.6.1	Passive Targeting	175-176
6.6.2	Active Targeting.....	176
6.6.3	Circulating Drug Reservoir in the Blood Compartment	177
6.6.4	Artificial Oxygen Delivery Systems	177
6.6.5	Blood-Pool Imaging	177
6.7	Clearance of Nanoparticles from Body.....	177-178
6.8	Stealth Nanoparticles	178-181
6.8.1	Poly(ethylene glycol) Anchored Stealth Nanoparticles.....	179-180
6.8.2	Circulation Kinetics of Stealth Particles.....	180-181
6.8.3	Toxicity of the Long Circulating Pegylated Nanoparticles	181
6.9	Conclusion	181-182
	References	182-185

CHAPTER 7

Nanoparticles and Targeted Systems for Cancer Diagnosis and Therapy

S. Asthana, Nitin K. Jain and Manish K. Chourasia..... 186-216

7.1	Introduction and Background	186-188
7.1.1	Cancer.....	186-187
7.1.1.1	TNM Cancer Staging	187
7.1.2	The Challenge of Cancer Therapy	187-188
7.1.3	Cancer Nanotechnology	188
7.2	Types of Nanoparticles as Delivery Systems.....	189-192
7.2.1	Polymer-based Drug Carriers	189-190
7.2.1.1	Polymeric Nanoparticles	189-190
7.2.1.2	Polymeric Micelles	190
7.2.1.3	Dendrimers.....	190

7.2.2	Lipid-based Drug Carriers.....	191
7.2.2.1	Liposomes.....	191
7.2.3	Carbon Nanotubes.....	191-192
7.3	Targeted Delivery of Nanoparticles.....	192-204
7.3.1	Size and Surface Characteristics of Nanoparticles.....	193-194
7.3.1.1	Size.....	193
7.3.1.2	Surface Characteristics.....	194
7.3.2	Passive targeting by Nanoparticles.....	194-196
7.3.2.1	Enhanced Permeability and Retention Effect.....	194-195
7.3.2.2	Tumor Microenvironment.....	196
7.3.3	Active Targeting by Nanoparticles.....	196-204
7.3.3.1	Folate Receptors.....	197-198
7.3.3.2	Targeting through Angiogenesis.....	198-200
7.3.3.3	Targeting to Specific Organs or Tumor Types.....	200-204
7.4	Cancer Diagnosis.....	204-207
7.4.1	Biopsy.....	204
7.4.2	Endoscopy.....	204
7.4.3	Blood Tests.....	204
7.4.4	Diagnostic Imaging.....	205-207
7.4.4.1	Ultrasound.....	205
7.4.4.2	X-rays.....	205
7.4.4.3	X-ray-based Computer-assisted Tomography or CT Scan.....	205
7.4.4.4	Radionuclide Imaging.....	205-206
7.4.4.5	Magnetic Resonance Imaging (MRI).....	206
7.4.4.6	Fluoresce Optical Imaging.....	206-207
7.5	Nanoparticulate Contrast Agents for Imaging.....	207-214
7.5.1	Inorganic Nanoparticles for Imaging.....	208-209
7.5.1.1	Fluorescent Nanoparticles for Optical Imaging.....	208

(xxiv) *Contents*

7.5.1.2 Magnetic Nanoparticles	209
7.5.1.3 Raman Probes	209-211
7.5.1.4 Colloidal Gold Nano-Rods/ Particles.....	211-212
7.5.2 Targeting Tumor Vasculature for Imaging.....	212-214
References	214-216

CHAPTER 8

Transdermal Drug Delivery Systems

<i>D. Mishra and P. Bhatnagar.....</i>	217-256
8.1 Introduction.....	217-220
8.1.1 Transdermal Drug Delivery System (TDDS)..	218-219
8.1.1.1 Merits of TDDS	219
8.1.1.2 Demerits of TDDS	219
8.1.2 Ideal Requirements of Drug for Transdermal Delivery	220
8.1.3 Topical v/s Transdermal Delivery	220
8.2 Anatomy and Physiology of Human Skin	221-223
8.2.1 Subcutaneous Tissue (ST).....	222
8.2.2 Functions of Human Skin	222
8.2.3 Possible Drug Delivery Channels <i>via</i> Skin	223
8.3 Factors Affecting TDDS.....	223-225
8.3.1 Physiological Factors	223-225
8.3.2 Dosage form Related Factors	225
8.3.3 Physiochemical Properties of Enhancers.....	225
8.4 Approaches for TDDS	226-229
8.4.1 Membrane Permeation Controlled TDDS	226-227
8.4.2 Polymer Matrix Diffusion Controlled TDDS..	227-228
8.4.3 Drug Reservoir Gradient Controlled TDDS.....	228
8.4.4 Microreservoir Dissolution Controlled TDDS	229
8.5 Transdermal Patches (TDP).....	230-233
8.5.1 How a TDP Works?	230
8.5.2 Conditions in which TDP can be used	231

8.5.3	Conditions in which TDP is not used	231
8.5.4	What Care should be taken while Applying a TDP?.....	231
8.5.5	Types of TDP	231-233
8.6	Generations of TDP	233-234
8.7	Components of TDP	234-236
8.7.1	Drug.....	234
8.7.2	Polymer Matrix.....	234
8.7.3	Permeation Enhancers	235
8.7.4	Pressure Sensitive Adhesive (PSA).....	235
8.7.5	Backing Laminate.....	235
8.7.6	Release Liner	236
8.7.7	Plasticizers.....	236
8.8	Methods of Preparation of TDP	236-238
8.8.1	Asymmetric Membrane TPX Method	236
8.8.2	Circular Teflon Mould Method	237
8.8.3	IPM Membrane Method	237
8.8.4	EVAC Membrane Method	237-238
8.9	Evaluation of TDP	238-241
8.9.1	Moisture Content Study.....	238-239
8.9.2	Tensile Strength Test.....	239-240
8.9.3	<i>In-Vitro</i> Release Study	240
8.9.4	Skin Permeation Study	240
8.9.5	<i>In-Vivo</i> Study.....	240-241
8.10	Clinical Trial Overview of TDP	241
8.11	Marketed TDP.....	241-242
8.12	Current Limitations of TDDS	242
8.13	Advancements in TDDS	242-253
8.13.1	Iontophoresis	243-244
8.13.2	Sonophoresis or Phonophoresis.....	244-245
8.13.3	Electrophoresis	245
8.13.4	Skin Ablation.....	246
8.13.5	Microneedle Technique (MN).....	246

(xxvi) *Contents*

8.13.6 Prodrug Method.....	247
8.13.7 Ion pair Method.....	247-248
8.13.8 Vesicular Systems	248-253
8.13.8.1 Transfersomes (TFS).....	249
8.13.8.2 Ethosomes (ES).....	251-252
8.13.8.3 Evaluation of TFS and ES.....	253
8.14 Future Prospects of TDDS.....	254
<i>References</i>	254-256

CHAPTER 9

Nanosized Materials used in Diagnosis

<i>Y. Singh and Manish K. Chourasia</i>	257-277
9.1 Introduction.....	257-259
9.2 Nanosized Materials used for Clinical Laboratory Diagnosis.....	259-271
9.2.1 Nanoparticles.....	259-271
9.2.1.1 Gold Nanoparticles	259-262
9.2.1.2 Quantum Dots	262-264
9.2.1.3 Dendrimers.....	264-266
9.2.1.4 Magnetic Nanoparticles	266-267
9.2.1.5 Polymeric Nanoparticles	267-269
9.2.1.6 Hybrid Particles	270-271
9.3 Carbon Nanotubes.....	271-274
9.4 NANO-BIOCHIP [LAB-ON-CHIP (LOC) Technique]	274
9.5 Toxicity Aspects of Nano-Diagnostics	275
9.6 Future Outlook.....	275-276
<i>References</i>	276-277

CHAPTER 10

Solid Lipid Nanoparticles: A Promising Colloidal Carrier

<i>D. Mishra, V. Dhote and P. K. Mishra</i>	278-301
10.1 Introduction.....	278-281

10.2	Solid Lipid Nanoparticles (SLN).....	281-284
10.2.1	Mechanism of Preparation of SLN.....	282
10.2.2	Advantages of SLN.....	283
10.2.3	Disadvantages of SLN.....	283
10.2.4	Aims of SLN Preparation.....	283-284
10.2.5	Components of SLN.....	284
10.3	Formulation of SLN.....	285-289
10.3.1	High Pressure Homogenization (HPH).....	285-286
10.3.1.1	Hot HPH.....	285
10.3.1.2	Cold HPH.....	286
10.3.2	Ultrasonic Homogenization.....	286-287
10.3.3	Micro-Emulsion based Method.....	287
10.3.4	Spray Drying Technique.....	288
10.3.5	Supercritical Fluid (SCF) Method.....	288-289
10.4	Ancillary Processing of SLN.....	289-290
10.5	Exsiccation of SLN.....	290
10.6	Characterization of SLN.....	290-293
10.6.1	Particle Size.....	291
10.6.2	Zeta Potential.....	291-292
10.6.3	Drug Content Estimation.....	292
10.6.4	Differential Scanning Calorimetry (DSC).....	292
10.6.5	Fourier Transform Infrared Spectroscopy (FTIR).....	292
10.6.6	X-ray Diffraction.....	292
10.6.7	<i>In vitro</i> Drug Release.....	293
10.6.8	Stability Studies.....	293
10.7	Route of SLN Administration.....	293-295
10.7.1	Oral Route.....	293-294
10.7.2	Topical Route.....	294
10.7.3	Parenteral Route.....	294-295
10.7.4	Pulmonary Administration.....	295
10.8	Pharmaceutical Applications of SLN.....	295-297
10.8.1	Cosmetics Vehicle.....	296

(xxviii) *Contents*

10.8.2 Drug Carrier	296
10.8.3 Gene Delivery.....	296
10.8.4 Targeted Delivery.....	296-297
References	297-301

CHAPTER 11

Niosomes Mediated Drug Delivery

J.G. Meher, M. Chaurasia and Manish K. Chourasia.... **302-329**

11.1 Introduction.....	302-308
11.1.1 Classification	304-306
11.1.1.1 Elastic Niosomes	304-305
11.1.1.2 Proniosomes	305
11.1.1.3 Discomes	305
11.1.1.4 Aspasomes.....	305
11.1.1.5 Surfactant Ethosomes	306
11.1.1.6 Bola Surfactant Niosomes	306
11.1.2 Advantages and Disadvantages	306
11.1.3 Root of Administration.....	307-308
11.1.3.1 Oral.....	307
11.1.3.2 Transdermal.....	307-308
11.1.3.3 Ocular	308
11.2 Materials used in Niosomes Preparation.....	309-312
11.2.1 Non-Ionic Surfactants.....	309-311
11.2.2 Additives	311-312
11.2.2.1 Cholesterol.....	311
11.2.2.2 Charged Molecules	311-312
11.2.3 Dispersion Medium	312
11.3 Methods of Preparation of Niosomes	312-316
11.3.1 Reverse Phase Evaporation Method	312-313
11.3.2 Ether Injection Method.....	313
11.3.3 Trans-Membrane pH Gradient Method	313-314
11.3.4 Sonication Method	314
11.3.5 Lipid Layer Hydration Method	315

11.3.6	Bubbling of Nitrogen Method	315
11.3.7	Extrusion Method	315
11.3.8	Hand Shaking Method	316
11.3.9	High Pressure Homogenization	316
11.4	Characterization	316-321
11.4.1	Size, Shape and Surface Morphology	317-318
11.4.2	Vesicle Charge	318
11.4.3	Entrapment Efficiency (EE)	318-319
11.4.4	<i>In vitro</i> Drug Release	319-320
11.4.5	<i>In vitro</i> Toxicity	320
11.4.6	<i>In vivo</i> Studies	320-321
11.4.7	Stability	321
11.5	Factors affecting the Preparation of Niosomes	321-323
11.5.1	Method of Preparation	321-322
11.5.2	Effect of Excipients	322
11.5.3	Effect of Temperature	322-323
11.5.4	Effect of pH of the Dispersion Medium	323
11.5.5	Effect of Encapsulated Drug	323
11.6	Applications	323-326
11.6.1	Controlled/Sustained Drug Delivery	324
11.6.2	Modulation of Physicochemical Characteristics of Drug	324
11.6.3	Transdermal Delivery	324-325
11.6.4	Pulmonary Delivery	325
11.6.5	Treatment of Infectious Disease	325
11.6.6	Ophthalmic Delivery	325
11.6.7	Vaccine Delivery	326
11.6.8	Protein and Peptide Delivery	326
11.6.9	Cancer Chemotherapy	326
11.7	Future Prospects	326-327
	References	327-329

CHAPTER 12

Microparticles as Drug Delivery Systems

<i>J.G. Meher and Manish K. Chourasia</i>	330-407
12.1 Introduction.....	330-338
12.1.1 A Brief History of Microparticles	333-334
12.1.2 Types of Microparticles.....	334-337
12.1.3 Salient Features and Drawbacks.....	338
12.2 Pharmaceutical Excipients and Active Pharmaceutical Ingredients used in Microparticles	338-348
12.2.1 Polymers.....	339-344
12.2.2 Solvents	345
12.2.3 Cross Linking Agents.....	346
12.2.4 Stabilizers	347
12.2.5 Active Pharmaceutical Ingredients (Core Material)	347-348
12.3 Preformulation Aspects in Microparticles	348-350
12.3.1 Physicochemical Characteristics of API and excipients	349
12.3.2 Inter-Excipients and Drug-Excipients Compatibility.....	349-350
12.4 Microparticles Preparation Techniques	350-365
12.4.1 Interfacial Polymerization	351-354
12.4.1.1 Dispersion Polymerization	351-352
12.4.1.2 Emulsion Polymerization	352-353
12.4.1.3 Suspension Polymerization	353-354
12.4.2 Emulsion Solvent Evaporation	354-356
12.4.2.1 Single Emulsion	354-355
12.4.2.2 Double Emulsion.....	355-356
12.4.3 Coacervation Phase Separation	356-361
12.4.3.1 Salt Addition.....	357-358
12.4.3.2 Non-Solvent Addition	358-359
12.4.3.3 Temperature Change	359-360

12.4.3.4	Polymer-Polymer Interaction	360
12.4.3.5	Incompatible Polymer Addition	360-361
12.4.4	Spray drying and Congealing	361-362
12.4.5	Advanced Methods	362-365
12.4.5.1	Extrusion Method	363
12.4.5.2	Supercritical Fluid Method.....	363
12.4.5.3	Ink-/liquid-jet Technology.....	363-364
12.4.5.4	Microsieve Technology	364
12.4.5.5	Microfluidics Technique	364-365
12.4.5.6	Electrospray Technique.....	365
12.5	Characterization of Microparticles	365-376
12.5.1	Size, Shape, Charge and Surface Morphology	365-366
12.5.2	Flow Properties.....	366-367
12.5.3	Thermal Analysis	367
12.5.4	Encapsulation Efficiency (EE)	367-368
12.5.5	<i>In vitro</i> Drug Release	368-369
12.5.6	<i>Ex vivo</i> Drug Permeation.....	369-370
12.5.7	<i>In vitro</i> Toxicity.....	370-371
12.5.8	Specific Analysis based on Type of Microparticles	371-372
12.5.9	<i>In vivo</i> Imaging of Microparticles	372-373
12.5.10	Stability Studies.....	373-374
12.5.11	<i>In vivo</i> Studies	374-375
12.5.12	<i>In vitro-in vivo</i> Correlation (IVIVC)	375-376
12.6	Sterilization of Microparticles	376-377
12.7	Factors Influencing Microparticle Formulation-Development and Characteristics	377-382
12.7.1	Method of Preparation.....	377-379
12.7.2	Pharmaceutical Excipients, API and Other Raw Materials	379-381
12.7.3	Temperature.....	381
12.7.4	pH of Solvents	381-382

(xxxii) *Contents*

12.8	Scale up in Microparticles	382-383
12.9	Pharmaceutical Applications	383-398
12.9.1	Sustained, Controlled and Targeted Drug Delivery	384-385
12.9.2	Topical and Transdermal Drug Delivery	385-386
12.9.3	Nasal and Pulmonary Drug Delivery	386-388
12.9.4	Oral Drug Delivery	388-391
12.9.5	Parenteral Drug Delivery	391-392
12.9.6	Ocular Drug Delivery	392-393
12.9.7	Protein and Gene Delivery	393-394
12.9.8	Vaccine Delivery	394-395
12.9.9	Enzyme and Growth Factor Delivery	395-396
12.9.10	Radio Diagnostics	396-397
12.9.11	Miscellaneous Applications	397-398
12.10	Future Prospectives	398
	<i>References</i>	398-407
	<i>Index</i>	409-420